Drug Profile
Research programme: therapeutic antibodies - Pfizer/Visterra
Alternative Names: Therapeutic antibodies - Visterra/PfizerLatest Information Update: 06 Sep 2018
Price :
$50
*
At a glance
- Originator Pfizer; Visterra
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 31 Aug 2018 Visterra has been acquired by Otsuka Pharmaceutical
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)
- 11 Sep 2012 Early research in Undefined indication in USA (Parenteral)